Full-Time

Director of Clinical Affairs

Eight Sleep

Eight Sleep

201-500 employees

Thermoregulated smart mattress with sleep tracking

Compensation Overview

$200k - $250k/yr

+ Equity + Performance-based incentives

Boston, MA, USA + 1 more

More locations: San Francisco, CA, USA

Hybrid

Hybrid work is required; the position is based in Boston or San Francisco.

Bachelor's, Master's, PhD, MD

Category
Biology & Biotech (1)
Required Skills
Data Science
FDA Regulations

Get referred to Eight Sleep

See people who can refer or advise you

Requirements
  • At least 10 years of hands-on clinical operations experience, including at least 5 years in leadership roles, executing clinical studies for FDA-regulated medical devices, software as a medical device, digital health products, or combination products.
  • A track record of designing, running, and translating clinical trials into regulatory approvals and marketed products.
  • Leadership or critical participation in trials that led to new FDA clearances or approvals or meaningful labeling expansions.
  • Experience managing third-party clinical sites, including site selection, activation, monitoring, and close-out.
  • Ability to author Institutional Review Board or Ethics submissions, informed consent forms, and clinical protocols.
  • At least 7 years of cross-functional program management involving clinical, engineering, and regulatory teams.
  • Working knowledge of clinical data management, including electronic case report form design, data cleaning, query management, and database lock processes.
  • Fluency in FDA device regulations, including Investigational Device Exemption, De Novo, and 510(k) clinical requirements; ICH-GCP; ISO 14155; and software as a medical device-specific guidance.
  • Experience with clinical study budgeting, vendor management, and contract research organization oversight.
  • Familiarity with documenting and adjudicating adverse events, device deficiencies, and associated reporting requirements.
  • A history of cultivating key opinion leader relationships for protocol development, research partnerships, study subcommittees, manuscripts, presentations, symposia, and related activities.
  • A bachelor's degree.
  • Ability to draft protocols, conduct site initiation visits, and present enrollment updates to executives.
  • ACRP or SOCRA certification is a plus.
Responsibilities
  • Lead study design with internal management, regulatory advisors, reimbursement specialists, and key opinion leader advisory committees to support clearance, payer coverage, and revenue goals.
  • Own clinical study execution from protocol development through the final study report, including feasibility, site selection, activation, enrollment management, monitoring, and close-out.
  • Write and manage Institutional Review Board and Ethics submissions, informed consent forms, and essential study documents.
  • Select, qualify, and oversee third-party clinical sites and investigators while serving as the primary contact for site teams.
  • Manage clinical data operations, including case report form and electronic case report form design, data review, query resolution, and coordination with data management vendors or internal teams.
  • Communicate directly with study sites and subjects as needed to resolve issues in real time.
  • Develop and maintain study timelines, budgets, and risk mitigation plans; flag issues, propose solutions, and report to leadership.
  • Ensure compliance with FDA regulations, including 21 CFR Parts 11, 50, 56, 812, and 820, ICH-GCP, ISO 14155, and applicable software as a medical device guidance.
  • Manage relationships with contract research organizations and other clinical vendors, including contract negotiation, performance oversight, and issue resolution.
  • Collaborate with regulatory affairs, product, engineering, data science, and legal teams to align clinical strategies with product development and submission timelines.
  • Support regulatory interactions with the FDA and other notified bodies or agencies, including preparation of pre-submissions, 510(k) submissions, and other correspondence.
  • Build and scale the clinical operations function by developing standard operating procedures, templates, tracking systems, and scalable processes.
Desired Qualifications
  • An advanced degree such as a Master of Science, Master of Public Health, PhD, or clinical doctorate.
  • Experience with biosensing devices, consumer health technology, or wellness platforms pursuing clinical validation.
  • Familiarity with real-world evidence study designs and decentralized or hybrid clinical trial models.
  • Experience in a high-growth startup or scale-up environment building processes from the ground up.
  • Experience supporting FDA breakthrough device designations or pre-submission meetings.

Eight Sleep sells hardware and subscription software to improve sleep quality. Its Pod Cover is a smart mattress cover with an Active Grid of water tubes connected to an external Hub; it heats or cools the bed and offers dual-zone climate control, while sensors track sleep stages, heart rate, HRV, and breathing to drive real-time temperature adjustments. The latest Pod 4 Ultra adds an adjustable base to reduce snoring, and the company charges for hardware plus a recurring app subscription, aiming to bundle more features into AI-powered sleep health tools. Its goal is to improve sleep and recovery while expanding into clinically applicable solutions and potential FDA-cleared health features.

Company Size

201-500

Company Stage

Late Stage VC

Total Funding

$312.2M

Headquarters

New York City, New York

Founded

2014

Get referred to Eight Sleep

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • March 2026 funding lifted Eight Sleep to a $1.5 billion valuation and unicorn status.
  • Abu Dhabi’s August 6, 2026 study expands credibility with clinicians and population-health buyers.
  • Aston Martin F1’s February 2026 partnership proves premium demand among performance-focused customers.

What critics are saying

  • Eight Sleep sued Orion Longevity on March 6, 2026, signaling aggressive copycat competition.
  • Subscription dependence stays exposed; hardware buyers still need paid tiers for full functionality.
  • FDA sleep-apnea ambitions create an existential failure mode if regulators block medical claims.

What makes Eight Sleep unique

  • Eight Sleep’s Pod 5 combines temperature control, biometrics, and auto-elevation in one bed system.
  • Its 2026 Tether partnership adds on-device AI via QVAC, strengthening privacy and latency.
  • Clinical ambition differentiates it: Abu Dhabi’s August 2026 sleep-apnea study validates medical positioning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

Commuter Benefits

Parental Leave

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

-2%
Abu Dhabi Media Office
Aug 6th, 2026
Department of Health - Abu Dhabi and Eight Sleep partner to study how AI could manage sleep apnoea.

Department of Health - Abu Dhabi and Eight Sleep partner to study how AI could manage sleep apnoea. * home * Health * Department of Health - Abu Dhabi and Eight Sleep partner to study how AI could manage sleep apnoea. The Department of Health - Abu Dhabi (DoH) and Eight Sleep, the global leader in sleep technology, have collaborated to study how AI-powered sleep technology could provide a new approach to managing conditions like sleep apnoea. The partnership will begin with a first-of-its-kind clinical study in Abu Dhabi that connects real-world data from Eight Sleep's technology with Abu Dhabi's population health data. The initial study will focus on sleep apnoea, one of the most widespread and underdiagnosed sleep-related conditions globally. It will examine how smart bed technology, including real-time adjustments to body position, may help improve how the condition is managed. During the 12-week study, Eight Sleep's technology will capture continuous sleep and physiological signals such as heart rate, breathing rate, movement, snoring, and positional data. Uniquely, this information will be connected into Abu Dhabi's intelligent health system, allowing researchers to analyse these signals alongside participants real-time health data, including relevant clinical, genomic and lifestyle data, to identify patterns that may help to inform future treatment pathways and clinical research. The study will be conducted by Sheikh Shakhbout Medical City, an Abu Dhabi medical research hospital, and will operate with built-in oversight, governance, and data protection protocols. Her Excellency Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health - Abu Dhabi, said: "Quality sleep is one of the strongest foundations of long-term health, yet common sleep disorders like sleep apnoea can significantly undermine it, raising the risk of serious health conditions when left unmanaged. Our collaboration with Eight Sleep reflects Abu Dhabi's commitment to the future of health: using data, research, and innovation to predict risk, intervene earlier, and improve outcomes. By generating real-world evidence from consumer sleep technology and integrating it with Abu Dhabi's intelligent health system, we can help inform personalised care pathways for people with sleep apnoea and other related disorders affecting sleep." The findings are expected to contribute to the evidence base for how consumer health technology can be responsibly integrated into clinical care and preventive health models. The research will also help evaluate how continuous sleep monitoring can complement existing clinical assessments and support future healthcare planning across the emirate. Matteo Franceschetti, Co-founder and CEO of Eight Sleep, said: "Sleep is one of the most powerful signals of human health, yet it has historically been undermeasured and underutilised in medicine," said. "This partnership with the Department of Health - Abu Dhabi is an important step toward making sleep a core pillar of preventive care. By combining Eight Sleep's continuous sleep data with Abu Dhabi's world-class health intelligence infrastructure, we can help generate the clinical evidence needed to personalise interventions, support earlier action, and improve health outcomes over time." Dr Marwan Al Kaabi, Chief Executive Officer, Sheikh Shakhbout Medical City, said: "Clinical research plays a critical role in transforming promising innovations into evidence that can improve patient care. Through this collaboration, Sheikh Shakhbout Medical City is helping evaluate how emerging technologies can be rigorously assessed within real-world clinical settings to generate insights that inform future models of care. As an academic medical centre, we are committed to advancing research that supports more personalised, preventive and data-driven healthcare, creating lasting value for patients, clinicians and the wider health system." Affecting nearly one billion people globally, sleep apnoea is a complex condition associated with increased risks of hypertension, type 2 diabetes, cardiovascular disease and cognitive decline. Symptoms often develop gradually and vary from night to night, so continuous monitoring has the potential to support earlier detection, more personalised interventions, and improved long-term management. While the initial study focuses on sleep apnoea, DoH and Eight Sleep plan to study how sleep, temperature regulation, and recovery effect other areas of health, such as menopause and cancer care. The findings are expected to help show how everyday consumer health devices can be used safely and responsibly within clinical care and prevention. The collaboration reinforces Abu Dhabi's continued investment in clinical research, health intelligence and responsible adoption of emerging technologies. By generating evidence within real-world care settings, the DoH continues to evaluate new approaches that can strengthen preventive health and improve long-term patient outcomes.

Bitget
Jun 28th, 2026
Tether leads $50M Eight Sleep funding round at $1.5B valuation

Tether has led a $50 million investment round in Eight Sleep, an AI sleep tracking startup, valuing the company at $1.5 billion. The funding follows a $100 million round raised by Eight Sleep in August 2025. Eight Sleep develops AI-powered sleep health technology, including the Eight Sleep Pod, which monitors biometric data such as heart rate, breathing and sleep stages. The system automatically adjusts bed temperature, elevation and sound settings based on real-time sleep patterns. The partnership will integrate Tether's QVAC architecture, which processes health data locally on devices rather than external servers. Eight Sleep is developing a predictive AI sleep agent trained on over one billion hours of sleep data and pursuing FDA filings for sleep apnoea detection. The investment reflects Tether's expansion beyond cryptocurrency into sectors including health technology and artificial intelligence.

CNET
May 5th, 2026
Eight Sleep's new Pregnancy Mode adjusts your bed temperature so you don't have to.

Eight Sleep's new Pregnancy Mode adjusts your bed temperature so you don't have to. The sleep tech company's latest feature tracks physiological changes during pregnancy and postpartum to automatically fine-tune your sleep. Nasha Addarich Martínez May 5, 2026 6:00 a.m. PT If you've ever been pregnant (or know someone who has), you know that sleep gets harder as the pregnancy progresses. One minute you're freezing, the next you're waking up to night sweats. Most likely, your sleep environment hasn't changed, but your body has. Eight Sleep, the company behind the Pod smart mattress cover and sleep tracker, just launched Pregnancy Mode, an AI-powered system built for the physiological changes brought on from pregnancy and postpartum. It's available now as a free app update for all Eight Sleep members with a paid Standard, Enhanced or Elite subscription ($17 to $33 per month). When you activate Pregnancy Mode within the app, the system uses your pre-pregnancy temperature baseline, your last menstrual period date and your estimated due date to automatically calculate weekly temperature adjustments across all sleep stages. Eight Sleep's dataset of over 100 pregnant members and 50,000 nights of sleep data found that in the early stages of pregnancy, your body tends to sleep warmer (about 0.4 to 0.7 degrees Fahrenheit) than your pre-pregnancy baseline temperature. The study also found that by the third trimester, it's the complete opposite - pregnant people were setting their Pods nearly 3.5 degrees cooler than normal. Pregnancy Mode also tracks that curve and continues to adjust eight weeks postpartum. The feature includes a dedicated Pregnancy Insights card in the app, where you can see weekly biometric summaries of your heart rate, heart rate variability, respiratory rate, sleep stages and snoring. It'll also compare these metrics to your pre-pregnancy scores. Baby development milestones and prenatal visit reminders are part of this new feature, too. Partners sharing the bed will get their own weekly insights on what to expect and how to help their pregnant significant other. Pregnancy Mode is now available in the Eight Sleep app on iOS and Android. The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives. Other sleep guides. Bed Accessories Sleep Tech NASHA ADDARICH MARTÍNEZ Managing Editor Nasha is a Managing Editor for CNET, overseeing its sleep and wellness verticals. She is a nutrition, mental health, fitness and sleep science enthusiast. Her passion for mindful and holistic practices transcends her personal life and profoundly influences her editorial approach, as she weaves evidence-based insights with practical advice to inspire readers to lead healthier, more balanced lives. Throughout her career, she's covered various topics including financial services, technology, travel and wellness. See full bio

Forge Global
Apr 6th, 2026
Q1's unicorns: from sleep optimization to blockchain intelligence.

Q1's unicorns: from sleep optimization to blockchain intelligence. By Chris Cannon Updated on April 6, 2026 The first quarter of 2026 has already produced a new cohort of unicorns spanning health tech, AI infrastructure, climate intelligence, biotech manufacturing and crypto compliance. From sleep optimization to blockchain intelligence, this latest group of companies reaching $1 billion valuations reflects a broader shift toward businesses embedding intelligence into real-world systems. Below, Forge Global, Inc. highlight five companies that achieved coveted unicorn status in Q1 2026. Eight Sleep, an AI-powered sleep system. New York City-based Eight Sleep is first on the list, having achieved unicorn status in Q1 2026. In March, the company closed a $50 million Series D funding round, bringing its post-money valuation to $1.5 billion.[1] Founded in 2014, Eight Sleep develops AI-powered sleep systems, including its flagship "Pod," which integrates biometric sensors and temperature regulation to optimize sleep performance.[2] The company noted that the latest capital raise will support expansion into clinical validation, FDA pathways, and a broader vision of proactive health monitoring, effectively transforming the bedroom into a continuous health data platform.[3] Eight Sleep has also been expanding its global footprint. In 2025, the company entered the Asia market with a suite of products launched in China and Singapore, and at the time indicated potential plans for a future public listing.[4] As of March 31, 2026, Eight Sleep's Forge Price(TM) is $3.50, implying a valuation of $653.80 million. Notable investors include Valor Equity Partners, Y Combinator, Founders Fund and SoftBank. Talos, a digital portfolio management platform. New York City-based Talos is next on the list, reaching unicorn status following a Series B funding round in January 2026 that valued the company at $1.5 billion. Founded in 2018, Talos provides trading and portfolio management software for institutional investors operating in digital asset markets. Its platform connects liquidity providers, exchanges and custodians into a unified system, enabling more efficient execution and streamlined risk management.[5] Since its founding, Talos has reportedly supported over $727 billion in trading volume, underscoring its growing role in institutional crypto infrastructure. The company plans to use its latest capital infusion to accelerate product development and expand its offerings across multiple digital asset classes.[6] Talos' last price per share was $50.02 as of its most recent funding round (Series B) on January 29, 2026.[7] Notable investors include General Atlantic, PayPal Ventures, Fidelity and Wells Fargo. Cellares, a healthcare company. In January 2026, healthcare company Cellares reached unicorn status after closing a $257 million Series D funding round at a $1.37 billion valuation. Founded in 2019, Cellares is a cell therapy manufacturer focused on developing scalable solutions to accelerate treatment access for patients across a range of diseases. The company noted that its latest capital raise will support the commercial launch of its cell therapies, with the goal of expanding access to thousands of patients each year.[8] Central to its platform is the Cell Shuttle, an automated system that enables end-to-end manufacturing of cell therapies. The technology was recognized as one of TIME's Best Inventions of 2025.[9] San Francisco-based Cellares reported a price per share of $11.99 as of its Series D round. Notable investors include BlackRock, Eclipse Ventures, T. Rowe Price and Bristol Myers Squibb. Tomorrow.io, a weather intelligence firm. Boston-based Tomorrow.io reached unicorn status in February 2026 after closing a $175 million Series F funding round, bringing its post-money valuation to $1 billion. Founded in 2015, Tomorrow.io is a weather intelligence company focused on delivering hyper-local, short-term forecasts. Its real-time solutions support decision-making across industries including aviation, logistics and government.[10] The company's differentiated approach combines proprietary data collection, such as satellite infrastructure, with AI-driven forecasting models. In January, Tomorrow.io unveiled "DeepSky," a constellation of satellites designed to provide atmospheric data to power AI models.[11] As of its most recent funding round (Series F) on February 3, 2026, Tomorrow.io's share price was $5.45 [12] Notable investors include Activate Capital, Square Peg Capital and HarbourVest. TRM Labs, an AI-powered crypto detective. San Francisco-based TRM Labs joined the unicorn ranks in February 2026 after closing a $70 million funding round that valued the fintech company at $1 billion. Founded in 2017, TRM Labs provides AI-powered tools that help governments, law enforcement and financial institutions detect and prevent illicit crypto activity. As digital asset adoption accelerates and regulatory scrutiny intensifies, the company is emerging as a critical infrastructure layer for financial integrity and national security.[13] More recently, TRM Labs introduced Co-Case Agent(TM), an AI investigative assistant designed to translate natural language prompts into actionable intelligence, streamlining complex blockchain investigations.[14] TRM Labs' last price per share was $24.74 as of its latest Series C funding round, February 4,2026.[15] Notable investors include Blockchain Capital, Goldman Sachs, Bessemer Venture Partners and Y Combinator.

TechCrunch
Mar 4th, 2026
Eight Sleep raises $50M at $1.5B valuation | TechCrunch

Eight Sleep said it was free-cash-flow positive in 2025 and plans to use the new funding for new products, global expansions, and clinical validation.